524 related articles for article (PubMed ID: 16218777)
1. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice.
Li H; Lu H; Griscelli F; Opolon P; Sun LQ; Ragot T; Legrand Y; Belin D; Soria J; Soria C; Perricaudet M; Yeh P
Gene Ther; 1998 Aug; 5(8):1105-13. PubMed ID: 10326034
[TBL] [Abstract][Full Text] [Related]
3. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
[TBL] [Abstract][Full Text] [Related]
4. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
5. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
[TBL] [Abstract][Full Text] [Related]
6. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
[TBL] [Abstract][Full Text] [Related]
7. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.
Kim KS; Hong YK; Lee Y; Shin JY; Chang SI; Chung SI; Joe Y
Exp Mol Med; 2003 Dec; 35(6):578-85. PubMed ID: 14749538
[TBL] [Abstract][Full Text] [Related]
8. [Experimental study of anti-metastasis effect of urokinase amino-terminal fragment gene on human breast cancer cells].
Zhu F; Xing G; He F
Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):115-7. PubMed ID: 11783013
[TBL] [Abstract][Full Text] [Related]
9. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
10. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis.
Gondi CS; Lakka SS; Yanamandra N; Siddique K; Dinh DH; Olivero WC; Gujrati M; Rao JS
Oncogene; 2003 Sep; 22(38):5967-75. PubMed ID: 12955075
[TBL] [Abstract][Full Text] [Related]
11. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
[TBL] [Abstract][Full Text] [Related]
12. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
[TBL] [Abstract][Full Text] [Related]
13. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
14. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
[TBL] [Abstract][Full Text] [Related]
15. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice.
Gondi CS; Lakka SS; Dinh DH; Olivero WC; Gujrati M; Rao JS
Clin Cancer Res; 2007 Jul; 13(14):4051-60. PubMed ID: 17634529
[TBL] [Abstract][Full Text] [Related]
17. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread.
Sato S; Kopitz C; Schmalix WA; Muehlenweg B; Kessler H; Schmitt M; Krüger A; Magdolen V
FEBS Lett; 2002 Sep; 528(1-3):212-6. PubMed ID: 12297307
[TBL] [Abstract][Full Text] [Related]
18. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
[TBL] [Abstract][Full Text] [Related]
19. Systemic delivery of antiangiogenic adenovirus AdmATF induces liver resistance to metastasis and prolongs survival of mice.
Li H; Griscelli F; Lindenmeyer F; Opolon P; Sun LQ; Connault E; Soria J; Soria C; Perricaudet M; Yeh P; Lu H
Hum Gene Ther; 1999 Dec; 10(18):3045-53. PubMed ID: 10609663
[TBL] [Abstract][Full Text] [Related]
20. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
